Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-
coronavirus 2 (SARS-CoV-2), has led to huge concern worldwide. Some SARS-CoV-2 …

The current COVID‐19 pandemic is caused by the SARS‐CoV‐2 coronavirus. The initial
recognized symptoms were respiratory, sometimes culminating in severe respiratory distress …

Pemphigus is a rare autoimmune blistering disease, involving potentially life-threatening
conditions often requiring immunosuppression. Currently, the COVID-19 pandemic caused …

Nowadays, the coronavirus disease 2019 (COVID-19) pandemic has become a global
health problem and, given the high mortality and transmission rate of this infection and the …

Since the beginning of the COVID-19 outbreak, attention has gradually moved from the
respiratory manifestations of the disease toward its dermatologic aspects. The need for …

Treatment of pemphigus vulgaris (PV) patients, as a chronic bullous disease, with
immunosuppressive agents could affect the course of COVID-19 (1). Nowadays, rituximab …

Pemphigus vulgaris (PV), an autoimmune blistering disease is treated with
immunosuppressive medications. As the immunosuppressive effect of rituximab, the first …

Rituximab is a monoclonal antibody that targets CD20, a B‐lymphocyte antigen; that leads to
a decline in the B‐cell counts for at least a year. The patients who have received rituximab …

COVID‐19 is a serious multisystem disease caused by severe acute respiratory syndrome
coronavirus 2. Due to the COVID‐19 crisis, that still keeps its impacts worldwide, numerous …

Aggressive course of pemphigus vulgaris following COVID-19 infection Exacerbation of
lesions secondary to administration of rituximab has been reported but COVID-19 positivity …